top of page
Home
About us â–¾
About KGbio
Our Leadership Team
Our Stakeholders
Our Partners
Products and Services
Career
News & Events
Contact Us
Product Pipeline
Biosimilars
Novel Biologics
ASSET
INDICATION
REGIMEN
PHASE
1
PHASE
2
PHASE
3
REGISTRATION
COMMERCIAL
Nimotuzumab
EGFR
monoclonal
antibody
Stage
III
&
IV Head and neck cancer
On
-
going
Glioma
,
Pancreatic cancer
,
Stage
III
&
IV Head and neck cancer
2008
KG
-
001
PD
-
1
monoclonal
antibody
1
L small cell lung cancer
(
SCLC
)
On
-
going
1
L squamous
Non
-
small cell lung cancer
On
-
going
1
L non
-
squamous
Non
-
small cell lung cancer
On
-
going
KG
-
002
IL
-
7
Fc fusion protein
Triple Negative Breast Cancer
(
TNBC
)
On
-
going
KG
-
003
Erythropoietin Fc
-
fusion
protein
Chronic kidney disease (
CKD
)-
induced
anemia in non
-
dialysis
On
-
going
CKD
-
induced anemia in dialysis
On
-
going
Rituximab
CD
20
monoclonal
antibody
Non
-
Hodgkin
’
s Lymphoma
2020
Trastuzumab
HER
2
monoclonal
antibody
Adjuvant HER
2
+
breast cancer, metastatic
HER
2
+
breast cancer
,
gastric
/
GEJ cancers
2018
Bevacizumab
VEGF monoclonal
antibody
Metastatic colorectal
,
breast and lung
cancers
2022
MONOTHERAPHY
COMBINATION
DONE
On
-
going
b
ased on most advanced of FDA
,
EMA
,
PMDA
,
TGA
,
HSA or NMPA regulatory stage
&
&
&
Novel Biologics
Biosimilar
Contract Manufacturing
Novel
Biologics
Our novel biologics products focus on treatments in oncology and high specialty areas. These represent a combination of early and advanced stage assets.
Our Novel Biologics
Novel Biologics
Biosmilar
bottom of page
